Related Experiment Video

Updated: Dec 7, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.3K

Autoimmune Hepatitis: Clinical Characteristics and Predictors of Biochemical Response to Treatment

Abbas Ali Tasneem1, Nasir Hassan Luck1

  • 1Department of Hepatogastroenterology, Sindh Institute of Urology & Transplantation, Karachi, Pakistan.

Journal of Translational Internal Medicine
|September 28, 2020
PubMed

Insights

Autoimmune hepatitis (AIH) patients are often young and cirrhotic. High pre-treatment IgG and low post-treatment bilirubin predict a good response to immunosuppression therapy.

Area of Science:

  • Hepatology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune hepatitis (AIH) is a significant cause of chronic liver disease.
  • Understanding AIH clinical characteristics and treatment response factors is crucial for patient management.

Purpose of the Study:

  • To evaluate the clinical characteristics of AIH patients.
  • To identify factors predicting treatment response in AIH.

Main Methods:

  • Prospective observational study of 56 AIH patients diagnosed between 2017-2019.
  • Biochemical response assessed at three months post-treatment initiation.
  • Response defined by normalization or partial/persistent elevation of transaminases.

Main Results:

  • The majority of patients were female (73.2%) and young (53.6% < 25 years), with a high prevalence of cirrhosis (83.9%).
  • Negative autoimmune serology (35.7%) was linked to severe necroinflammation and esophageal varices.
  • Good treatment response (60.7%) was associated with pre-treatment serum IgG > 20 g/L and post-treatment total bilirubin < 2 mg/dL.

Conclusions:

  • AIH predominantly affects young, cirrhotic individuals.
  • Negative serology does not exclude AIH; liver biopsy may be necessary.
  • Pre-treatment IgG levels and post-treatment bilirubin are independent predictors of treatment success.
Abstract

Keywords:
autoimmune hepatitisclinical characteristicstreatment response

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.7K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment &#8212; Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
101
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
125
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
119